Peter Svennilson

Director at NGM Bio.

Raised on NGM Bio filings

$142M

of $142M offered across 1 Form D filing

Form D filings: 1
Teammates: 3
Last filing: Mar 27, 2026

Company

Biotech · South San Francisco, CA

Antibody drugs for pregnancy nausea and cancer wasting

Antibody drugs for pregnancy nausea and cancer wasting

Investors: 26
Founded: 2024

Investors: 26
Sector: Biotech
Founded: 2024
HQ: South San Francisco, CA

NGM Bio filings

NGM Bio Form D filings
Filed	Security	Sold of offered	Filing
Mar 27, 2026	Equity	$142M/ $142M	Form D/A

EquityFiled Mar 27, 2026Form D/A
$142M/ $142M

Works with

Also named on NGM Bio filings

Diana Peng BockusChief Executive Officer, Form D signerForm D signer Tim KutzkeyDirector Roger M. PerlmutterDirector